B. Riley Wealth Advisors Inc. Buys New Shares in Grifols, S.A. (NASDAQ:GRFS)

B. Riley Wealth Advisors Inc. bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 56,950 shares of the biotechnology company’s stock, valued at approximately $359,000.

Several other large investors have also recently bought and sold shares of GRFS. Cohen Investment Advisors LLC bought a new stake in Grifols in the 1st quarter valued at $80,000. AQR Capital Management LLC bought a new stake in Grifols in the 2nd quarter valued at $89,000. Morningstar Investment Services LLC bought a new stake in Grifols in the 4th quarter valued at $186,000. Cetera Advisors LLC bought a new stake in shares of Grifols in the 1st quarter worth about $147,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Grifols by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 9,350 shares during the last quarter.

Grifols Stock Down 0.4 %

GRFS opened at $8.88 on Tuesday. The firm’s 50-day simple moving average is $8.37 and its 200-day simple moving average is $7.55. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of 8.71 and a beta of 0.50.

Grifols (NASDAQ:GRFS) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a return on equity of 1.73% and a net margin of 0.90%. The firm had revenue of $1.96 billion during the quarter. Equities research analysts anticipate that Grifols, S.A. will post 0.79 EPS for the current fiscal year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.